scout
Opinion|Videos|November 29, 2023

Momelotinib in MF: Data from the SIMPLIFY-1 Trial

The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME